Novel fucogangliosides found in human colon adenocarcinoma tissues by means of glycomic analysis.
The structures of acidic glycosphingolipids in colon adenocarcinoma have been analyzed extensively using a number of conventional methods, such as thin-layer chromatography and methylation analysis, and a variety of acidic glycosphingolipids present in the tissues have been reported. However, because of a number of limitations in the techniques used in previous studies in terms of resolution, quantification, and sensitivity, we employed a different method that could be applied to small amounts of tissue. In this technique, the carbohydrate moieties of acidic glycosphingolipids from approximately 20mg of colon adenocarcinoma were released by endoglycoceramidase II and were labeled by pyridylamination. They were separated and structurally characterized by a two-dimensional HPLC mapping technique, electrospray ionization tandem mass spectrometry (ESI-MS/MS), and enzymatic cleavage. A total of 22 major acidic glycosphingolipid structures were identified, and their relative quantities were revealed in detail. They are composed of 1 sulfated (SM3), 1 lacto-series (SLe(a)), 6 kinds of ganglio-series, and 14 kinds of neolacto-series glycosphingolipids. They include most of the acidic glycosphingolipids previously reported to be present in the tissues and two previously unknown fucogangliosides sharing the same terminal structure: NeuAcalpha2-6(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc, and NeuAcalpha2-6(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3-Galbeta1-4Glc. Thus, this highly sensitive, high-resolution analysis enabled the identification of novel structures of acidic glycosphingolipids from small amounts of already comprehensively studied cancerous tissues. This method is a powerful tool for microanalysis of glycosphingolipid structures from small quantities of cancerous tissues and should be applicable to different types of malignant tissues.
Korekane
Hiroaki
H
Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-2 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.
Tsuji
Satoyo
S
Noura
Shingo
S
Ohue
Masayuki
M
Sasaki
Yo
Y
Imaoka
Shingi
S
Miyamoto
Yasuhide
Y
D020384:Acidic Glycosphingolipids / Q000737:chemistry / Q000302:isolation & purification*; D000230:Adenocarcinoma / Q000737:chemistry*; D000631:Aminopyridines / Q000737:chemistry; D014408:Biomarkers, Tumor / Q000737:chemistry / Q000302:isolation & purification*; D002240:Carbohydrate Sequence; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003110:Colonic Neoplasms / Q000737:chemistry*; D005643:Fucose / Q000737:chemistry; D005732:Gangliosides / Q000737:chemistry / Q000302:isolation & purification*; D005782:Gels / Q000737:chemistry; D006026:Glycoside Hydrolases / Q000378:metabolism; D006801:Humans; D025942:Oligosaccharides, Branched-Chain / Q000737:chemistry* / Q000302:isolation & purification; D021241:Spectrometry, Mass, Electrospray Ionization; D053719:Tandem Mass Spectrometry
D020384:Acidic Glycosphingolipids; D000631:Aminopyridines; D014408:Biomarkers, Tumor; D005732:Gangliosides; D005782:Gels; D025942:Oligosaccharides, Branched-Chain; C031153:fucogangliosides; D005643:Fucose; D006026:Glycoside Hydrolases; C050427:endoglycoceramidase; C032439:alpha-aminopyridine